HIV-1 matrix protein p17: A candidate antigen for therapeutic vaccines against AIDS

Pharmacology and Therapeutics

Volumn 128, Issue 3, 2010, Pages 433-444

  Fiorentini, Simona ^a   Giagulli, Cinzia ^a   Caccuri, Francesca ^a   Magiera, Anna K ^b   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Medestea Research   (Italy)

Author keywords

AIDS; Clinical trial; HIV matrix protein p17; HIV 1 immunopathogenesis; Peptide based immunization; Therapeutic vaccine

Indexed keywords

EPITOPE; HIV 1 MATRIX PROTEIN P17; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MATRIX PROTEIN; PROTEIN P17; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; GENE CONTROL; GOOD MANUFACTURING PRACTICE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; LIFE CYCLE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG EVALUATION, PRECLINICAL; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNITY, CELLULAR; PEPTIDES;

EID: 78049281873     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.08.005     Document Type: Review

References (207)

1. Abel K., La Franco-Scheuch L., Rourke T., Ma Z.M., De Silva V., Fallert B., et al. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J Virol 2004, 78:841-854.
2. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
3. AIDS Vaccine Evaluation Group 022 Protocol Team Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001, 183:563-570.
4. Akiyama H., Ido E., Akahata W., Kuwata T., Miura T., Hayami M. Construction and in vivo infection of a new simian/human immunodeficiency virus chimera containing the reverse transcriptase gene and the 3' half of the genomic region of human immunodeficiency virus type 1. J Gen Virol 2003, 84:1663-1669.
5. Alfadhli A., Barklis R.L., Barklis E. HIV-1 matrix organizes as a hexamer of trimers on membranes containing phosphatidylinositol-(4, 5)-bisphosphate. Virology 2009, 387:466-472.
6. Allain J.P., Laurian Y., Deborah A.P., Verroust F., Leuther M., Gazengel C., et al. Long-term evaluation of HIV antigen and antibodies to p24 and gp4l in patients with hemophilia. N Eng J Med 1987, 317:114-121.
7. Altfeld M.A., Livingston B., Reshamwala N., Nguyen P.T., Addo M.M., Shea A., et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptidebinding motif. J Virol 2001, 75:1301-1311.
8. Altfeld M., Rosenberg E.S., Shankarappa R., Mukherjee J.S., Hecht F.M., Eldridge R.L., et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001, 193:169-180.
9. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63-75.
10. - T cells: Certainties and uncertainties of a prevalent T-cell subset. Immunol Cell Biol 2002, 80:1-13.
11. + T cell homeostasis and function in advanced HIV disease. Science 1997, 277:11211-11216.
12. Autran B., Debré P., Walker B., Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 2003, 3:503-508.
13. Autran B., Murphy R.L., Costagliola D., Tubiana R., Clotet B., Gatell J., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008, 22:1313-1322.
14. Avolio M., Caracciolo S., Tosti G., Vollero L., Fiorentini S., Caruso A. HIV-1 matrix protein p17 prevents loss of CD28 expression during IL-2-induced maturation of naïve CD8(+) T cells. Viral Immunol 2008, 21:189-202.
15. - human T cells. J Immunol 2000, 165:1910-1917.
16. Barron M.A., Blyveis N., Palmer B.E., MaWhinney S., Wilson C.C. Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in HIV-1-infected individuals. J Infect Dis 2003, 187:26-37.
17. Baur A., Vornhagen R., Korn K., Sonneborn H.H., Eberlein B., Harrer T., et al. Viral culture and p24 antigenaemia of human immunodeficiency virus (HIV) infected individuals correlated with antibody profiles determined with recombinant polypeptides of all HIV-1 open-reading frames. J Infect Dis 1992, 165:419-426.
18. Beausejour Y., Tremblay M.J. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J Infect Dis 2004, 190:894-902.
19. Besançon F., Just J., Bourgeade M.F., Van Weyenbergh J., Solomon D., Guillozo H., et al. HIV-1 p17 and IFN-gamma both induce fructose 1, 6-bisphosphatase. J Interferon Cytokine Res 1997, 17:461-467.
20. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001, 75:11983-11991.
21. Bhatia A., Campbell N., Panganiban A., Ratner L. Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. Virology 2007, 369:47-54.
22. Biancotto A., Grivel J.C., Iglehart S.J., Vanpouille C., Lisco A., Sieg S.F., et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007, 109:4272-4279.
23. Binley J.M., Klasse P.J., Cao Y., Jones I., Markowitz M., Ho D.D., et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 1997, 71:2799-2809.
24. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
25. Bird J.J., Brown D.R., Mullen A.C., Moskowitz N.H., Mahowald M.A., Sider J.R., et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998, 9:229-237.
26. - T cells. AIDS 1994, 8:431-441.
27. Boutwell C.L., Rowley C.F., Essex M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol 2009, 83:2460-2468.
28. Brander C., Hartman K.E., Trocha A.K., Jones N.G., Johnson R.P., Korber B., et al. Lack of strong immune selection pressure by the immunodominant, HLAA* 0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998, 101:2559-2566.
29. Brander C., Walker B.D. Gradual adaptation of HIV to human host populations: Good or bad news?. Nat Med 2003, 9:1359-1362.
30. Brown K.N., Wijewardana V., Liu X., Barratt-Boyes S.M. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog 2009, 5:e1000413.
31. Bryant M., Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A 1990, 87:523-527.
32. + in culture of human T cells derived from peripheral blood of adult donors and cord blood of newborns. Mech Ageing Dev 2003, 124:379-387.
33. Bukrinsky M.I., Haggerty S., Dempsey M.P., Sharova N., Adzhubel A., Spitz L., et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
34. Buratti E., Tisminetzky S.G., D'Agaro P., Baralle F.E. A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. J Virol 1997, 71:2457-2462.
35. Cadogan M., Dalgleish A.G. HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis 2008, 8:675-684.
36. - T cells with impaired effector functions in HIV-1-infected patients. J Acquir Immune Defic Syndr 2000, 24:465-474.
37. Caruso A., Pollara P., Foresti I., Bonfanti C., De Francesco M., Gelmi M., et al. Interferon-gamma is associated with the surface of the human immunodeficiency virus and binds to the gag gene product p17. AIDS Res Hum Retroviruses 1989, 5:605-612.
38. Chargelegue D., Stanley C.M., O'Toole C.M., Colvin B.T., Steward M.W. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 1995, 99:175-181.
39. Check E. Scientists rethink approach to HIV gels. Nature 2007, 446:12.
40. Chehimi J., Campbell D.E., Azzoni L., Bacheller D., Papasavvas E., Jerandi G., et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002, 168:4796-4801.
41. Cheingsong-Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 1991, 302:23-26.
42. Chopera D.R., Woodman Z., Mlisana K., Mlotshwa M., Martin D.P., Seoighe C., et al. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog 2008, 4:e1000033.
43. Chuenchitra T., Wasi C., Louisirirojchanakul S., Nitayaphan S., Sutthent R., Cox J.H., et al. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. AIDS Res Hum Retroviruses 2003, 19:293-305.
44. Cicala C., Arthos J., Martinelli E., Censoplano N., Cruz C.C., Chung E., et al. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc Natl Acad Sci U S A 2006, 103:3746-3751.
45. Cinque P., Vago L., Mengozzi M., Torri V., Ceresa D., Vicenzi E., et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998, 12:1327-1332.
46. Cohen J. AIDS research. Microbicide fails to protect against HIV. Science 2008, 319:1026-1027.
47. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current Protocols in Immunology 1996, vol. 2:9.0.1-9.8.15. John Wiley & Sons, New York.
48. Conant K., Garzino-Demo A., Nath A., McArthur J.C., Halliday W., Power C., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998, 95:3117-3121.
49. + T-cell effector activity in HIV primary infection. J Clin Invest 1999, 104:1431-1439.
50. Dalton A., Ako-Adjei D., Murray P., Murray D., Vogt V. Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain. J Virol 2007, 81:6434-6445.
51. Davis M., Jiang J., Zhou J., Freed E., Aiken C. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of envelope protein subunits gp120 and gp41. J Virol 2006, 80:2405-2417.
52. De Francesco M.A., Baronio M., Fiorentini S., Signorini C., Bonfanti C., Poiesi C., et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci U S A 2002, 99:9972-9977.
53. De Francesco M.A., Caruso A., Fallacara F., Canaris A.D., Dima F., Poiesi C., et al. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS 1998, 12:245-252.
54. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3.
55. Dingwall C., Laskey R.A. Nuclear targeting sequences a consensus?. Trends Biochem Sci 1991, 16:478-481.
56. Dong X., Li H., Derdowski A., Ding L., Burnett A., Chen X., et al. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 2005, 120:663-674.
57. Douek D.C. Disrupting T-cell homeostasis: How HIV-1 infection causes disease. AIDS Rev 2003, 5:172-177.
58. + T cells. Nature 2002, 417:95-98.
59. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
60. + T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002, 76:2298-2305.
61. Edwards C.T., Pfafferott K.J., Goulder P.J., Phillips R.E., Holmes E.C. Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeficiency virus type 1 at the population level. J Virol 2005, 79:9363-9366.
62. Eguchi Y., Srivanasan A., Tomaselli K.J., Shimizu S., Tsujimoto Y. ATP-dependent steps in apoptotic signal transduction. Cancer Res 1999, 59:2174-2181.
63. Estcour M.J., McMichael A.J., Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 2004, 199:144-155.
64. - lymphocytes from HIV+ patients. J Clin Immunol 2001, 21:135-144.
65. Facke M., Janetzko A., Shoeman R.L., Krausslich H.G. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol 1993, 67:4972-4980.
66. Fantuzzi L., Spadaro F., Vallanti G., Canini I., Ramoni C., Vicenzi E., et al. Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood 2003, 102:2334-2337.
67. Feeney M.E., Tang Y., Roosevelt K.A., Leslie A.J., McIntosh K., Karthas N., et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 2004, 78:8927-8930.
68. Fenouillet E., Blanes N., Coutellier A., Demarquest J., Rozenbaum W., Gluckman J.C., et al. Monitoring of antibodies against human immunodeficiency virus type I p24 core protein as prognostic marker. J Infect Dis 1992, 166:611-616.
69. Fiorentini S., Marini E., Bozzo L., Trainini L., Saadoune L., Avolio M., et al. Preclinical studies on immunogenicity of the HIV-1 p17 based synthetic peptide AT20-KLH. Biopolymers 2004, 76:334-343.
70. Fiorentini S., Marini E., Caracciolo S., Caruso A. Functions of the HIV-1 matrix protein p17. New Microbiol 2006, 29:1-10.
71. Fiorentini S., Marsico S., Becker P.D., Iaria M.L., Bruno R., Guzmán C.A., et al. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine 2008, 26:4758-4765.
72. Fiorentini S., Riboldi E., Facchetti F., Avolio M., Fabbri M., Tosti G., et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci U S A 2008, 105:3867-3872.
73. Flamminio G., Caruso A., Poiesi C., Bonfanti C., Terlenghi L., Canaris A.D., et al. Aspects of molecular interaction between HIV p17 and human gamma interferon. AIDS Res Hum Retroviruses 1995, 11:1441-1447.
74. Fonteneau J.F., Larsson M., Beignon A.S., McKenna K., Dasilva I., Amara A., et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004, 78:5223-5232.
75. Förster R., Schubel A., Breitfeld D., Kremmer E., Renner-Müller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
76. Fouchier R.A., Meyer B.E., Simon J.H., Fischer U., Malim M.H. HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 1997, 16:4531-4539.
77. Frahm N., Adams S., Kiepiela P., Linde C.H., Hewitt H.S., Lichterfeld M., et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 2005, 79:10218-10225.
78. Freed E.O. HIV-1 gag proteins: Diverse functions in the virus life cycle. Virology 1998, 251:1-15.
79. Freed E.O. HIV-1 Gag: Flipped out for PI(4, 5)P2. Proc Natl Acad Sci U S A 2006, 103:11101-11102.
80. Freed E.O., Orenstein J.M., Buckler-White A.J., Martin M.A. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 1994, 68:5311-5320.
81. Gallina A., Mantoan G., Rindi G., Milanesi G. Influence of MA internal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 Gag protein. Biochem Biophys Res Commun 1994, 204:1031-1038.
82. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 1999, 96:8324-8326.
83. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000, 165:1082-1092.
84. Gelderblom H.R. Assembly and morphology of HIV: Potential effect of structure on viral function. AIDS 1991, 5:617-637.
85. Gheysen D., Jacobs E., De Foresta F., Thiriart C., Francotte M., Thines D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989, 59:103-112.
86. Goebel F.D., Mannhalter J.W., Belshe R.B., Eibl M.M., Grob P.J., de Gruttola V., et al. Recombinant gp160 as a therapeutic vaccine for HIV-infection: Results of a large randomized controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group. AIDS 1999, 13:1461-1468.
87. Göttlinger H.G., Sodroski J.G., Haseltine W. A role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1989, 86:5781-5785.
88. Gould S.J., Booth A.M., Hildreth J.E. The Trojan exosome hypothesis. Proc Natl Acad Sci U S A 2003, 100:10592-10597.
89. Goulder P.J., Altfeld M.A., Rosenberg E.S., Nguyen T., Tang Y., Eldridge R.L., et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001, 193:181-194.
90. Goulder P.J., Brander C., Tang Y., Tremblay C., Colbert R.A., Addo M.M., et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001, 412:334-338.
91. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
92. Goulder P.J., Sewell A.K., Lalloo D.G., Price D.A., Whelan J.A., Evans J., et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997, 185:1423-???.
93. Goulder P.J., Watkins D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008, 8:619-630.
94. Gray E.S., Madiga M.C., Moore P.L., Mlisana K., Abdool Karim S.S., Binley J.M., et al. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009, 83:11265-11274.
95. Gringeri A., Santagostino E., Muca-Perja M., Mannucci P.M., Zagury J.F., Bizzini B., et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol 1998, 1:293-298.
96. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
97. Guihot A., Tubiana R., Breton G., Marcelin A.G., Samri A., Assoumou L., et al. Immune and virological benefits of 10years of permanent viral control with antiretroviral therapy. AIDS 2010, 24:614-617.
98. Haffar O.K., Popov S., Dubrovsky L., Agostini I., Tang H., Pushkarsky T., et al. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol 2000, 299:359-368.
99. Harlow D.L. Antibodies: A laboratory manual 1988, 72-87. Cold Spring Harbor Laboratory, New York.
100. Herbein G., Khan K.A. Is HIV infection a TNF receptor signalling-driven disease?. Trends Immunol 2008, 29:61-67.
101. Hill C.P., Worthylake D., Bancroft D.P., Christensen A.M., Sundquist W.I. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Proc Natl Acad Sci U S A 1996, 93:3099-3104.
102. Hofmann B., Langhoff E., Lindhardt B.O., Odum N., Hyldig-Nielsen J.J., Ryder L.P., et al. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Cell Immunol 1989, 121:336-348.
103. Hogervorst E., Jurriaans S., de Wolf F., van Wijk A., Wiersma A., Valk M., et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: Low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995, 171:811-821.
104. Honey K. Microbicide trial screeches to a halt. J Clin Invest 2007, 117:1116.
105. Hosmalin A., Lebon P. Type I interferon production in HIV-infected patients. J Leukoc Biol 2006, 80:984-993.
106. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
107. Iversen A.K., Stewart-Jones G., Learn G.H., Christie N., Sylvester-Hviid C., Armitage A.E., et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 2006, 7:179-189.
108. Jiang J.D., Chu F.N., Naylor P.H., Kirkley J.E., Mandeli J., Wallace J.I., et al. Specific antibody responses to synthetic peptides of HIV-1 p17 correlate with different stages of HIV-1 infection. J Acquir Immune Defic Syndr 1992, 5:382-390.
109. Jin X., Ramanathan M., Barsoum S., Deschenes G.R., Ba L., Binley J., et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002, 76:2206-2216.
110. Jouvenet N., Neil S., Bess C., Johnson M., Virgen C., Simon S., et al. Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol 2006, 4:2296-2310.
111. Kaplan A.H., Swanstrom R. HIV-1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A 1991, 88:4528-4532.
112. Kaslow R.A., Carrington M., Apple R., Park L., Muñoz A., Saah A.J., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
113. Kaul M., Lipton S.A. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 2006, 4:307-318.
114. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
115. Kinloch-de Loes S., Hoen B., Smith D.E., Autran B., Lampe F.C., Phillips A.N., et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005, 192:607-617.
116. Kinter A., Arthos J., Cicala C., Fauci A.S. Chemokines, cytokines and HIV: A complex network of interactions that influence HIV pathogenesis. Immunol Rev 2000, 177:88-98.
117. Kinter A.L., Poli G., Fox L., Hardy E., Fauci A.S. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995, 154:2448-2459.
118. Kootstra N.A., Schuitemaker H. Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. Virology 1999, 253:170-180.
119. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
120. Lange J.M.A., De Wolf F., Krone W.J.A., Danner S.A., Coutinho R.A., Goudsmit J. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than p24 decline. AIDS 1987, 1:155-159.
121. Lawn S.D., Butera S., Folks T.M. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001, 14:753-777.
122. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
123. Liang X., Casimiro D.R., Schleif W.A., Wang F., Davies M.E., Zhang Z.Q., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79:12321-12331.
124. Liao M., Lu Y., Xiao Y., Dierich M.P., Chen Y. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine. Peptides 2000, 21:463-468.
125. Lipman M., Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006, 19:20-25.
126. Liu Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005, 23:275-306.
127. Llibre J.M., Falco V., Tural C., Negredo E., Pineda J.A., Muñoz J., et al. The changing face of HIV/AIDS in treated patients. Curr HIV Res 2009, 7:365-377.
128. + dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS 2002, 16:683-692.
129. MacGregor R.R., Boyer J.D., Ugen K.E., Tebas P., Higgins T.J., Baine Y., et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine 2005, 23:2066-2073.
130. Mandl J.N., Barry A.P., Vanderford T.H., Kozyr N., Chavan R., Klucking S., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087.
131. Marini E., Tiberio L., Caracciolo S., Tosti G., Guzman C.A., Schiaffonati L., et al. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: Role of transcriptional factor AP-1. Cell Microbiol 2008, 10:655-666.
132. Markowitz M., Jin X., Hurley A., Simon V., Ramratnam B., Louie M., et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002, 186:634-643.
133. Massiah M.A., Starich M.R., Paschall C., Summers M.F., Christensen A.M., Sundquist W.I. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol 1994, 244:198-223.
134. Matthews S., Barlow P., Boyd J., Barton G., Russell R., Mills H., et al. Structural similarity between the p17 matrix protein of HIV-1 and interferon-gamma. Nature 1994, 370:666-668.
135. McGaughey G.B., Barbato G., Bianchi E., Freidinger R.M., Garsky V.M., Hurni W.M., et al. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res 2004, 2:193-204.
136. McMichael A.J. HIV vaccines. Annu Rev Immunol 2006, 24:227-255.
137. McMichael A., Klenerman P. HIV/AIDS. HLA leaves its footprints on HIV. Science 2002, 296:1410-1411.
138. Mehta S.U., Rupprecht K.R., Hunt J.C., et al. Prevalence of antibodies to the core protein p17, a serological marker during HIV-1 infection. AIDS Res Hum Retroviruses 1990, 6:443-454.
139. Miedema F. A brief history of HIV vaccine research: Stepping back to the drawing board?. AIDS 2008, 22:1699-1703.
140. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci 2000, 197:2709-2714.
141. Misumi S., Endo M., Mukai R., Tachibana K., Umeda M., Honda T., et al. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. J Biol Chem 2003, 278:32335-32343.
142. Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V., Gargalianos P., et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998, 352:1725-1730.
143. Moore C.B., John M., James I.R., Christiansen F.T., Witt C.S., Mallal S.A. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002, 296:1439-1443.
144. Morikawa Y., Zhang W.H., Hockley D.J., Nermut M.V., Jones I.M. Detection of a trimeric human immunodeficiency virus type 1 gag intermediate is dependent on sequences in the matrix protein, p17. J Virol 1998, 72:7659-7663.
145. Murray P.S., Li Z., Wang J., Tang C.L., Honig B., Murray D. Retroviral matrix domains share electrostatic homology: models for membrane binding function throughout the viral life cycle. Structure 2005, 13:1521-1531.
146. Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M.J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
147. Naylor P.H., Naylor C.W., Badamchian M., Wada S., Goldstein A.L., Wang S.S., et al. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci U S A 1987, 84:2951-2955.
148. Nehete P.N., Chitta S., Hossain M.M., Hill L., Bernacky B.J., Baze W., et al. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 2001, 20:813-825.
149. Nguyen D.G., Booth A., Gould S.J., Hildreth J.E. Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem 2003, 278:52347-52354.
150. Nickel W. The mystery of nonclassical protein secretion: A current view on cargo proteins and potential export routes. Eur J Biochem 2003, 270:2109-2119.
151. O'Brien S.J., Gao X., Carrington M. HLA and AIDS: A cautionary tale. Trends Mol Med 2001, 7:379-381.
152. Ono A., Freed E.O. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004, 78:1552-1563.
153. Ono A., Orenstein J.M., Freed E.O. Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol 2000, 74:2855-2866.
154. Ostrom R.S., Gregorian C., Insel P.A. Cellular release of and response to ATP as key determinants of the set-point of signal transduction pathways. J Biol Chem 2000, 275:11735-11739.
155. Paillart J., Gottlinger H. Opposing effects of human immunodeficiency virus type 1 Gag to membrane: Role of the matrix amino terminus. J Virol 1999, 73:2604-2612.
156. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
157. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.G., Demarest J.F., et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
158. Papsidero L.D., Sheu M., Ruscetti F.W. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: Characterization and epitope mapping. J Virol 1989, 63:267-272.
159. Pelchen-Matthews A., Kramer B., Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 2003, 162:443-455.
160. Penna G., Sozzani S., Adorini L. Selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001, 167:1862-1866.
161. Pialoux G., Quercia R.P., Gahery H., Daniel N., Slama L., Girard P.M., et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: The LIPTHERA study. Clin Vaccine Immunol 2008, 15:562-568.
162. Plana M., García F., Gallart T., Tortajada C., Soriano A., Palou E., et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14:1921-1933.
163. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.J., van Lunzen J., Lewis G., et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2005, 102:14807-14812.
164. Pulliam L., Gascon R., Stubblebine M., McGuire D., McGrath M.S. Unique monocyte subset in patients with AIDS dementia. Lancet 1997, 349:692-695.
165. + T cells: A mechanism of immune evasion. FASEB J 2004, 18:1459-1461.
166. Reil H., Bukovsky A.A., Gelderblom H.R., Göttlinger H.G. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J 1998, 17:2699-2708.
167. Reinhart T.A., Fallert B.A., Pfeifer M.E., Sanghavi S., Capuano S., Rajakumar P., et al. Increased expression of the inflammatory chemokine CXC chemokine ligand 9/monokine induced by interferon-gamma in lymphoid tissues of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. Blood 2002, 99:3119-3128.
168. Resh M. A myristoyl switch regulates membrane binding of HIV-1 Gag. Proc Natl Acad Sci U S A 2004, 101:417-418.
169. Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J.S., Quivy V., et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: Implications for treatment of latent infection. PLoS ONE 2009, 4:e6093.
170. Richard J.P., Melikov K., Brooks H., Prevot P., Lebleu B., Chernomordik L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005, 280:15300-15306.
171. Rivière L., Darlix J.L., Cimarelli A. Analysis of the viral elements required in the nuclear import of HIV-1 DNA. J Virol 2010, 84:729-739.
172. Robey W.G., Safai B., Oroszlan S., Arthur L.O., Gonda M.A., Gallo R.C., et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985, 228:593-595.
173. Saad J.S., Miller J., Tai J., Kim A., Ghanam R.H., Summers M.F. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci U S A 2006, 103:11364-11369.
174. Sandstrom E., Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo controlled trial, Nordic VAC-04 Study Group. Lancet 1999, 353:735-742.
175. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:757-769.
176. Scarlata S., Ehrlich L., Carter C. Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions. J Mol Biol 1998, 277:161-167.
177. Schmidt B., Scott I., Whitmore R.G., Foster H., Fujimuram S., Schmitz J., et al. Low-level HIV infection of plasmacytoid dendritic cells: Onset of cytopathic effects and cell death after PDC maturation. Virology 2004, 329:280-288.
178. Schneidewind A., Brockman M.A., Yang R., Adam R.I., Li B., Le Gall S., et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007, 81:12382-12393.
179. Sekaly R.P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?. J Exp Med 2008, 205:7-12.
180. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:131-136.
181. Simmons A., Aluvihare V., McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001, 14:763-777.
182. Soumelis V., Scott I., Gheyas F., Bouhour D., Cozon G., Cotte L., et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 2001, 98:906-912.
183. Sozzani S. Dendritic cell trafficking: More than just chemokines. Cytokine Growth Factor Rev 2005, 16:581-592.
184. Spearman P., Horton R., Ratner L., Kuli-Zade I. Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol 1997, 71:6582-6592.
185. Springer K.L., Weinberg A. Cytomegalovirus infection in the era of HAART: Fewer reactivations and more immunity. J Antimicrob Chemother 2004, 54:582-586.
186. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A 2004, 101:13026-13031.
187. Stone S.F., Price P., French M.A. Immune restoration disease: A consequence of dysregulated immune responses after HAART. Curr HIV Res 2004, 2:235-242.
188. Tang C., Loeliger E., Luncsford P., Kinde I., Beckett D., Summers M.F. Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad Sci U S A 2004, 101:517-522.
189. Tenzer S., Wee E., Burgevin A., Stewart-Jones G., Friis L., Lamberth K., et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009, 10:636-646.
190. Tyagi M., Rusnati M., Presta M., Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001, 276:3254-3261.
191. Joint united nations program on HIV/AIDS. AIDS epidemic update, December 2009 2009, UNAIDS.
192. Vandergeeten C., Quivy V., Moutschen M., Van Lint C., Piette J., Legrand-Poels S. HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha+TSA. Biochem Pharmacol 2007, 73:1738-1748.
193. Vicenzi E., Biswas P., Mengozzi M., Poli G. Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 1997, 62:34-40.
194. Vitale M., Caruso A., De Francesco M.A., Rodella L., Bozzo L., Garrafa E., et al. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br J Haematol 2003, 120:337-343.
195. Wahl S.M., Greenwell-Wild T., Peng G., Ma G., Orenstein J.M., Vazquez N. Viral and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc Biol 2003, 74:726-735.
196. Walker B.D., Korber B.T. Immune control of HIV: The obstacles of HLA and viral diversity. Nat Immunol 2001, 2:473-475.
197. Wang C.Y., Shen M., Tam G., Fang X.D., Ye J., Shen F. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002, 21:89-97.
198. Williams R., Yao H., Dhillon N.K., Buch S.J. HIV-1 Tat co-operates with IFN-gamma and TNF-alpha to increase CXCL10 in human astrocytes. PLoS ONE 2009, 4:e5709.
199. Wills J., Craven R. Form, function, and use of retroviral gag proteins. AIDS 1991, 5:639-654.
200. Yim H.C., Li J.C., Lau J.S., Lau A.S. HIV-1 Tat dysregulation of lipopolysaccharide-induced cytokine responses: Microbial interactions in HIV infection. AIDS 2009, 23:1473-1484.
201. Yokomaku Y., Miura H., Tomiyama H., Kawana-Tachikawa A., Takiguchi M., Kojima A., et al. Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 2004, 78:1324-1332.
202. + T-cell responses following acute HIV-1 infection. J Virol 2002, 76:8690-8701.
203. Yuan X., Yu X., Lee T.H., Essex M. Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 1993, 67:6387-6394.
204. + T cells. J Immunol 2005, 174:2196-2204.
205. Zhao J., Lai L., Amara R.R., Montefiori D.C., Villinger F., Chennareddi L., et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: Inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009, 83:4102-4111.
206. Zuñiga R., Lucchetti A., Galvan P., Sanchez S., Sanchez C., Hernandez A., et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006, 80:3122-3125.
207. Zwart G., van der Hoek L., Valk M., Cornelissen M.T., Baan E., Dekker J., et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 1994, 201:285-293.